Table 2.

Merlin expression levels and nuclear Survivin labeling index are independent prognosticators for clinical outcomes. Multivariate analysis (MV) of overall survival (OS) and freedom from recurrence (FFR). Parameters included in the analysis showed significant results in the univariate analysis.

Cohort 1
MV for OS	HRa	(95% CI b )	p
Gender
(Male vs female)	3.3	(1.5–7.7)	0.005
Cytoplasmic NF2 pre‐CTX
(High expression (>0.5) vs low expression (≤0.5))	0.5	(0.3–0.9)	0.01
Histological subtype pre CTX			0.003
Sarcomatoid vs epithelioid	7.7	(1.5–41.0)	0.02
Biphasic vs epithelioid	2.1	(1.2–3.6)	0.006
pT stage			0.04
pT2 vs. pT1	1.2	(0.5–2.9)	0.6
pT3 vs. pT1	1.0	(0.4–2.4)	1.0
pT4 vs. pT1	3.3	(1.1–9.6)	0.03
MV for FFR	HR	(95% CI)	p
Cytoplasmic NF2 pre‐CTX
(high expression (>0.5) vs low expression (≤0.5))	0.5	(0.3–1.0)	0.04
Survivin labeling index pre‐CTX
(High expression (>14%) vs low expression (≤14%))	3.4	(1.7–6.8)	0.001
pT stage			0.001
pT2 vs. pT1	2.9	(0.7–11.5)	0.1
pT3 vs. pT1	7.9	(2.0–32.0)	0.004
pT4 vs. pT1	18.3	(3.5–96.7)	0.001
Cohort 2
MV for OS	HR	(95% CI)	p
Age at diagnosis
> 61 years vs. ≤ 61 years	2.40	(1.28–4.50)	0.006
Survivin labeling index
> 10 vs. ≤ 10	2.35	(1.27–4.33)	0.006
MV for FFR	HR	(95% CI)	p
Age at diagnosis
> 61 years vs. ≤ 61 years	2.17	(1.06–4.42)	0.034
Gender
Male vs. female	3.03	(1.24–7.41)	0.015

^aHR, hazard ratio.

^bCI, confidence interval.